FDA has granted an Investigational New Drug (IND) application to Immorta Bio Inc. to initiate a clinical trial evaluating # the safety, immunogenicity, and efficacy of #30745 SenoVax™ in patients with advanced non-small cell lung cancer (NSCLC).
Thomas Ichim, PhD, President and Chief Scientific Officer of Immorta Bio, acknowledged the first clinical candidate SenoVax™ designed to prompt the immune system to target not the NSCLC cancer but the cells protecting it.
A recent study found that SenoVax therapy, while primarily aimed at reducing NSCLC tumor size, also sparked significant interest in its additional regenerative benefits.
Boris Reznik, PhD, Chairman and CEO of Immorta Bio, acknowledged the FDA for granting SenoVax™ and emphasized gratitude for the team and clinical and scientific collaborators who advanced the promising laboratory technology into a candidate for clinical assessment.
The SenoVax™ trial will enroll NSCLC patients who have exhausted standard treatment options and will assess the therapeutic potential of SenoVax in multiple dosing cohorts.
Immorta Bio’s research has demonstrated that SenoVax can inhibit SenoVax™ growth in animal models and induce immune responses against senescent cells in laboratory settings.
Source: Immorta Bio Files Investigational New Drug Application for First in Class Senolytic Immunotherapy SenoVax™ for Treatment of Advanced Lung Cancer
https://www.prnewswire.com/news-releases/immorta-bio-files-investigational-new-drug-application-for-first-in-class-senolytic-immunotherapy-senovax-for-treatment-of-advanced-lung-cancer-302207491.html
